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BACKGROUND. In breast carcinoma patients with a positive sentinel lymph node
(SN), the value of complete axillary lymph node dissection has been questioned.
Multiple published reports have attempted to identify clinicopathologic charac-
teristics of the primary tumor and SN that are associated with an increased
likelihood of positive nonsentinel lymph nodes (NSN). Because of differences in
lymph node evaluation techniques and limited patient numbers in each study, the
authors performed a meta-analysis to assess the regularity and relative strength of
association between various characteristics and the risk of NSN metastasis.
METHODS. A MEDLINE search identified 15 candidate studies, 11 of which met the
criteria for analysis. General elements of the studies, the pathologic characteristics
evaluated, and the results for selected characteristics were compared. Original data
were abstracted from each study and used to calculate odds ratios. The Mantel–
Haenszel common odds ratios were calculated to determine the relative strength of
the associations.
RESULTS. Despite methodologic differences, the correlation between positive
NSNs and certain pathologic characteristics was found to be remarkably similar
among studies. The 5 individual characteristics found to be associated with the
highest likelihood of NSN metastasis are SN metastasis  2 mm in size, extranodal
extension in the SN, tumor size  2 cm,  1 positive SN, and lymphovascular
invasion in the primary tumor.
CONCLUSIONS. There is general concordance among studies regarding the associ-
ation between pathologic characteristics and NSN metastasis in breast carcinoma
patients with a positive SN. The pooled analysis identified those factors with the
strongest associations that should be evaluated routinely in SN specimens and
included in prospective databases for the development of a predictive model.
Cancer 2003;98:2307–15. © 2003 American Cancer Society.
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Because of the acknowledged morbidity of axillary lymph nodedissection (ALND),1,2 sentinel lymph node (SN) biopsy has rapidly
emerged as the primary approach to staging the axillary lymph nodes
in patients with breast carcinoma. If the SN is positive, the standard
of care remains a completion ALND, but this has been questioned
because the survival benefit remains uncertain.3,4 Completion ALND
may also offer an advantage in terms of reduced regional recurrence
in patients who harbor residual axillary lymph node metastasis, but
many patients with positive SNs have no other positive axillary lymph
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nodes. There is general agreement that removal of
negative lymph nodes does not provide any significant
benefit. Therefore, the ability to predict the status of
the nonsentinel lymph nodes (NSNs), whether posi-
tive or negative, could help to tailor surgical therapy to
those individuals most likely to derive a benefit from
completion ALND. Patients with a predicted small
chance of residual axillary lymph node metastasis af-
ter a positive SN biopsy might be able to safely avoid
completion ALND. Conversely, prediction of the high
likelihood of residual axillary lymph node metastases
may identify patients for whom completion ALND is
necessary.
In an attempt to obtain predictive parameters,
multiple published studies have identified pathologic
characteristics of the primary tumor and SN that are
associated with an increased likelihood of additional
positive NSNs. Because of perceived regional and in-
stitutional differences in methods of obtaining and
evaluating lymph nodes, as well as limited patient
numbers in each study, we undertook a comparative
meta-analysis of these studies to assess the strength of
the associations of these characteristics with the pres-
ence of NSN metastasis and the consistency of these
findings across studies.
MATERIALS AND METHODS
To identify relevant articles, a MEDLINE search was
performed using the following keywords: nonsentinel
node, non-sentinel node, nonsentinel lymph node,
non-sentinel lymph node, sentinel lymph node biopsy
combined with breast neoplasms and characteristics,
sentinel lymph node biopsy combined with breast
neoplasms and predictors, and breast neoplasms
combined with axillary dissection and metastasis. Ar-
ticles from these searches with titles pertinent to the
topic were evaluated further. Articles included in the
meta-analysis were those that reported original data
regarding the association between various patient/
tumor characteristics and the likelihood of positive
NSNs. Criteria for inclusion in the meta-analysis were
as follows: 1) the study identified the population of
patients with a positive SN and who underwent com-
pletion ALND, 2) original data were reported on the
number of SN-positive patients who had positive
NSNs stratified by various patient/tumor characteris-
tics, 3) statistical analysis for these characteristics was
not based on groups that included patients with neg-
ative SNs, and 4) the study population included pa-
tients with both micrometastatic and macrometastatic
disease in the SNs. References cited in the selected
articles were reviewed for additional relevant reports,
and these studies were subjected to the same criteria
for inclusion. Studies that appeared to represent over-
lapping patient populations were evaluated for extent
of data; the study with lesser relevance was excluded.
Information was collected concerning the charac-
teristics of the studies, as well as the types of patient/
tumor characteristics examined and the level of statis-
tical significance. The numbers of patients with
positive and negative NSNs for each characteristic
were abstracted from each study. In some studies,
data were not presented for characteristics that were
not statistically significant. Therefore, a complete
dataset was not always obtainable for every character-
istic evaluated in each study. The accuracy of the
abstracted data was verified independently by an ex-
ternal consultant (ion Write, Saline, MI). These data
then were used to construct graphical representations
of the association between the selected characteristics
and positive NSNs (as determined by hematoxylin and
eosin [H & E] evaluation unless otherwise specified).
Study-specific odds ratios were calculated from the
abstracted data, and the common odds ratios across
studies were estimated using the Mantel–Haenszel
method.5 For the meta-analysis, data regarding NSNs
found to be positive by H & E evaluation were used
whenever available, but data from studies in which
immunohistochemistry (IHC) was performed on NSNs
were included. Point estimates and 95% confidence
intervals (95% CI) for the common odds ratios were
reported for characteristics supported by abstracted
data from at least 2 studies. The standard criterion of
P values  0.05 for hypothesis tests was used to de-
termine statistical significance for original calcula-
tions herein and when considering hypothesis tests
conducted by the individual study.
RESULTS
Based on the MEDLINE search, 15 candidate studies
were identified.3,6 –19 One study3 was excluded be-
cause of presumed overlap of the dataset with another
study.10 Two studies17,18 were excluded because the
evaluations were limited to patients with micrometa-
static disease in the SN, a group that was potentially
dissimilar from the populations of the remaining stud-
ies. A fourth study19 was excluded because the data
regarding completion ALND findings were correlated
with features among the collective group of SN cases;
data concerning the subset of SN-positive patients
were not reported.
The 11 studies included in the meta-analysis were
published between 1999 and 2003. The study sample
sizes (patients with a positive SN who underwent
completion ALND) ranged from 60 –389 patients. Pa-
tient age, the number of SNs obtained, and the num-
ber of NSNs obtained appeared similar across studies
(Table 1), although no explicit statistical testing of this
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hypothesis was possible given the format of the data.
In contrast, the study populations exhibited some ap-
parent variation in disease stage distribution; the pro-
portions of patients with tumors  2 cm and with SN
micrometastasis ranged from 30 –78% and 25–57%,
respectively.
The routine use of IHC and additional sections to
evaluate the NSNs may be the most important differ-
ence among the studies. The SN hypothesis was vali-
dated by confirming that IHC and additional section-
ing rarely detect NSN metastasis in patients with SNs
found to be negative by H & E staining and IHC.20,21
However, in patients with SNs found to be positive by
H & E staining or IHC, increased scrutiny of NSNs with
IHC and additional sections reportedly results in a
10 –20% increase in the detection of NSN metasta-
sis.21,22 Of the studies analyzed, five used only H & E
staining for the evaluation of NSNs.6,7,9,11,15 In addi-
tion to H & E staining, three studies performed IHC
and additional sections on NSNs. Of these 3 studies, 1
evaluated NSNs on 2 levels with a 250-m interval,8 1
evaluated NSNs on 2 levels with a 40-m interval,10
and 1 evaluated 3– 8 levels in the subgroup of patients
with primary tumors measuring  2 cm and micro-
metastasis in the SN.12 In the remaining three studies,
the histologic evaluation of the NSNs was not able to
be determined.13,14,16 One study reported data con-
cerning NSNs both with and without the use of IHC for
three characteristics: tumor size, metastasis size, and
lymphovascular invasion (LVI).10 Data regarding the
remaining factors reported in that study reflect the use
of IHC on NSNs. We constructed graphs based on data
reporting NSNs found to be positive by H & E evalu-
ation unless otherwise specified. As stated in the
“Methods” section, the meta-analysis utilized data re-
garding NSNs found to be positive by H & E evaluation
whenever available, but data from studies performing
IHC on NSNs also were included in the meta-analysis.
Table 2 presents the clinicopathologic character-
istics that were evaluated by at least two studies.
Whether the characteristic was found to have a statis-
tically significant association with the presence of
NSN metastasis is reported. Two studies reported ap-
parent differences in the proportion of NSN metasta-
sis based on tumor size and metastasis size but did not
perform a statistical test of that hypothesis.15,16 The
characteristics found to be statistically significant by
three or more studies were: tumor size, size of meta-
static focus within the SN, presence of extranodal ex-
tension (EE), presence of LVI, and the number of
positive SNs. Other characteristics that were found to
be associated significantly with NSN metastasis by
univariate analysis in only one study included higher
histologic grade, negative estrogen receptor status,
and three or more SNs removed.
In addition to the characteristics shown in Table
2, three additional factors were found to be signifi-
cantly associated with the presence of NSN metastasis,
each in a separate study. In one study that evaluated
the location of metastasis in the SN,13 a metastasis
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Abdessalam et al.6 2001 100 54 (30–83) 49 Dye  iso No 35 2.4  2.2b 22.1  8.6b
Weiser et al.7 2001 206 52 (21–85) 74 Dye  iso No 46 NR NR
Rahusen et al.8 2001 93 NR 57 Dye  iso Yes NA 1.7 (1–4)b NR
Wong et al.9 2001 389 NR 50 Dye, iso,
or both
No NR 2.2b,c 13b,c
Turner et al.10 2000 194 52 (28–91) 54 Dye  iso Yes 48 2 (1–7) 17 (7–59)
Hwang et al.11 2003 131 53 (30–78) 55 Dye  iso No 25 2 (1–8) 15 (3–37)
Reynolds et al.12 1999 60 56 (26–90) 60 Dye  iso Yes, for T1 with
micrometastasis
45 NR NR
Cserni13 2001 69 NR 30 Dye Unknown NA 1.4 (1–6)b,c 17 (5–42)b,c
Kamath et al.14 2001 101 NR NR Dye  iso Unknown 46 NR NR
Mignotte et al.15 2002 120 NR 78 Dye  iso No 57 1.8 (1–6)b,c NR
Canavese et al.16 2001 72 61 (40–79)b 68 Dye  iso Unknown 29 1.4 (1–4)b,c NR
IHC: immunohistochemistry; NSNs: nonsentinel lymph nodes; H & E: hematoxylin and eosin; SN: sentinel lymph nodes; isotope: ; NR: data not reported; NA: not applicable.
a Number of patients in the study who had a positive sentinel lymph node biopsy and completion axillary lymph node dissection.
b Reported as the mean (range) or mean  standard deviation.
c Calculated mean includes some patients with nonsentinel lymph nodes.
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confined to the sinusoid of a SN was associated with a
lower likelihood of positive NSNs than a metastasis in
the parenchyma of the SN. In the second study,11
patients receiving neoadjuvant chemotherapy prior to
axillary lymph node surgery were more likely to have
positive NSNs. The third study found that utilizing
IHC as the method of detection of metastasis in the SN
was correlated with a lower likelihood of NSN metas-
tasis,10 although it could be argued this is a surrogate
assessment of size of metastasis in the SN. Other char-
acteristics evaluated that were not found to be statis-
tically significant included type of breast procedure,9
mitotic count12 or mitotic activity index,8 palpable
axillary lymph node,10 S-phase fraction,10 and DNA
ploidy.10
The apparent increase in the proportion of posi-
tive NSNs as the tumor size increases is shown in
Figure 1. Despite some variability among the studies,
there appears to be general concordance that the pro-
portion of patients with positive NSNs increases with
increasing tumor size. The largest variability in the
proportions of patients with positive NSNs across
studies was found to occur in the subgroups with
the fewest patients (T1a, T3, and T4). The small
subgroup sample sizes may have contributed to this
variability.
A positive association between the size of the me-
tastasis in the SN and the proportion of patients with
positive NSNs is shown in Figure 2. In patients with
micrometastatic ( 2 mm) SN disease, approxi-
mately 13–22% are reported to have additional me-
tastasis by H & E staining in NSNs, in contrast to
45–79% of patients with macrometastatic ( 2 mm)
disease. In those studies that classified the SN me-
tastasis size as detected by IHC only,  2 mm ex-
cluding IHC-detected disease, or  2 mm, there was
a trend toward further discrimination among pa-
tients with micrometastatic disease (Fig. 3). It is
notable that even in the subgroup of patients with
SN micrometastases that were detectable only with
IHC, the chance of H & E-positive NSNs was found
to reach 20% (Fig. 3).
FIGURE 1. Effect of tumor size on the likelihood of positive nonsentinel lymph
nodes (NSN). The numbers indicate the proportion of patients with positive NSN
(by hematoxylin and eosin evaluation) for each subgroup. Please note that the
data from the study by Rahusen et al.8 included positive NSNs that were
detected with routine immunohistochemistry. The asterisk indicates that T1a
and T1b patients were combined in this group.
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Abdessalam et al.6  ●a ● ●        
Weiser et al.7 ● ● ●    
Rahusen et al.8b  ●     ● 
Wong et al.9 ●   ●  
Turner et al.10b ● ●a ● ● ●    ●  
Hwang et al.11 ● ●  ●       ● 
Reynolds et al.12b ● ●    ●  
Cserni13 ● ● ● 
Kamath et al.14 ● ●a
Mignotte et al.15 c a,c
Canavese et al.16 c c
NSN: nonsentinel lymph nodes; LVI: lymphovascular invasion; ER: estrogen receptor; PR: progesterone receptor; SNs: sentinel lymph nodes; Open circles; feature evaluated but not found to be statistically significant
by univariate analysis; Solid circles: feature found to be Statistically significant by univariate analysis.
a Included stratification for lymph nodes positive by immunohistochemistry only.
b Statistical significance calculation based on data that included nonsentinel lymph nodes determined to be positive with routine use of immunohistochemistry.
c Statistical analysis not reported.
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Three of four studies evaluating EE found a statis-
tically higher proportion of patients with positive
NSNs when EE was present (Fig. 4). Of the six studies
that evaluated LVI, four found a statistically significant
increase in the likelihood of positive NSNs when LVI
was present. However, the magnitude of this differ-
ence was less than that noted for tumor size, metas-
tasis size, or EE.
The estimates of the common odds ratios for
specified characteristics across studies, using the
Mantel–Haenszel method, are shown in Figure 5. The
common odds ratio and its 95% CI are presented.
Intervals that did not overlap the referent (1.0) were
considered to be statistically significant at the P  0.05
level. Table 3 reports the total sample size and the
sample distribution for the levels of the characteristics
compared in Figure 5, along with the range of the
calculated study-specific odds ratios. Using evaluation
of the common odds ratios, the individual character-
istics that demonstrated the strongest association with
NSN metastasis were SN metastasis measuring  2
mm, the presence of EE in the SN, tumor size  2 cm,
 1 positive SN, and LVI present in the primary tumor.
To our knowledge, these five characteristics also are
the only ones reported to be significantly associated
by the majority of studies that evaluated these factors
(Table 2).
Multivariate analysis performed in several of the
studies7,9-13 also confirmed the importance of these
five characteristics (Table 4). Each of the five charac-
teristics with the strongest association by the Mantel–
Haenszel meta-analysis was found to be statistically
significant by multivariate analysis in at least one
study, and there were no other features found to be
significant by multivariate analysis. One study re-
ported that metastasis size, LVI, and EE were all so
highly related that on multivariate analysis only one
FIGURE 2. Effect of metastasis size on the likelihood of positive nonsentinel
lymph nodes (NSN). The numbers indicate the proportion of patients with
positive NSN (by hematoxylin and eosin evaluation) for each subgroup. The
asterisk indicates that the data included positive NSNs detected with routine
immunohistochemistry.
FIGURE 3. Effect of metastasis size (immunohistochemistry [IHC] only) on the
likelihood of positive nonsentinel lymph nodes (NSN). The numbers indicate the
proportion of patients with positive NSN (by hematoxylin and eosin evaluation)
for each subgroup.
FIGURE 4. Effect of extranodal extension (EE) on the likelihood of positive
nonsentinel lymph nodes (NSN). The numbers indicate the proportion of
patients with positive NSN (by hematoxylin and eosin evaluation) for each
subgroup. The asterisk indicates that the data included positive NSNs detected
with routine immunohistochemistry (IHC).
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factor remained significant, although this factor was
not specified.6
DISCUSSION
Because of the lower morbidity associated with SN
biopsy compared with ALND,23 this method has be-
come widely utilized to stage the axilla in patients with
breast carcinoma. The primary benefit offered by SN
biopsy is the elimination of ALND in patients with
lymph node-negative disease. When a SN is positive,
completion ALND remains the standard of care. How-
ever, persistent concern for the morbidity of ALND
generates a parallel question in SN-positive patients:
can any of these individuals be spared a completion
ALND? To consider omitting completion ALND, clini-
cians need information regarding the likelihood of
additional axillary lymph node metastasis, as well as
outcomes when potential residual disease is not re-
sected.
The American College of Surgeons Oncology
Group (ACOSOG) is currently accruing patients to a
prospective trial that randomizes SN-positive lumpec-
tomy patients to completion ALND versus observa-
tion.24 We believe this study will provide definitive
data regarding the necessity of a standard ALND in
contributing to survival, as well as in obtaining dura-
ble regional control of disease after resection of at
least one metastatic SN. Encouraging patients to par-
ticipate in this important trial should be a high prior-
ity. However, it is likely that its mature results will not
be reported for several years. In the meantime, a pre-
dictive model to estimate the likelihood of a patient
harboring metastatic NSNs will remain valuable for
those cases in which the ACOSOG trial is not available,
and for patients who are ineligible for the study, such
as mastectomy patients. Knowledge of the clinico-
pathologic characteristics associated with NSN metas-
tasis may be helpful in the analysis of data and corre-
lation with outcome in this trial or future
investigations.
The results of the current meta-analysis demon-
strate that in the presence of any 1 of 5 characteristics
(SN metastasis size 2 mm, the presence of extran-
odal extension in the SN, tumor size  2 cm,  1
positive SN, or LVI present in the primary tumor),
there is a  2-fold increase in the likelihood of finding
additional metastasis in NSNs. Conversely, no sub-
group of patients identified by a single characteristic
consistently demonstrated a  10% chance of NSN
metastasis. Theoretically, patients lacking all five of
the pathologic features characteristics specified would
comprise this group; however, effective analysis for
this narrowly defined subgroup is limited by small
patient numbers, underscoring the importance of a
large dataset.
Although the data presented in the current study
are limited to the strength of associations of the indi-
vidual characteristics, there is remarkable similarity
reported among studies despite known differences in
protocols. One of the known differences—the variable
use of IHC to evaluate NSNs—is a concerning poten-
tial source of variation among the studies. As men-
tioned previously, in patients with H & E- or IHC-
positive SNs, increased scrutiny of NSNs with IHC and
additional sections is reported to result in a 10 –20%
increase in the detection of NSN metastasis.21,22 Five
studies included in the meta-analysis reported the
routine use of IHC, three did not routinely use IHC,
and in three studies the use of IHC was indeterminate.
Including studies that varied with regard to the use of
IHC on NSNs appears to decrease the homogeneity of
the dataset in the meta-analysis, but excluding studies
on this basis would markedly limit the size of the
dataset. In our opinion, the larger dataset afforded by
including all the studies justified this potential source
of variability. Furthermore, the graphical representa-
tion of study-specific results in Figures 1-4 allows the
reader to correlate results based on the likelihood of
positive NSNs with use of IHC.
Based on the meta-analysis, the size of the meta-
static focus in the SN appears to demonstrate the
strongest association with the likelihood of positive
NSNs, and the lowest likelihood of positive NSNs
noted for any single characteristic occurred in the
subgroup with IHC-detected metastasis. Although
controversial, the use of IHC on SNs is not recom-
mended currently.25 Therefore, a predictive model
that incorporates this feature may have compromised
FIGURE 5. Mantel–Haenszel meta-analysis of odds ratios for selected
features. PR: progesterone receptor; SNs: sentinel lymph nodes; ER: estrogen
receptor.
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applicability when pathologic evaluation of the SN
does not include IHC. IHC detection of metastasis in
the SN is essentially a surrogate determination of
small metastasis size. Because the size of the metas-
tasis in the SN appears to be the single most important
feature, a predictive model based on a more refined
categoric distinction of metastasis size (or incorpora-
tion of the actual measured size of the metastasis as a
continuous variable) might provide an alternative and
more applicable approach to distinguish those pa-
tients least likely to have NSN metastasis. This poten-
tial advantage would have to be weighed against the
disadvantage of requiring a pathologic measurement
that is not routinely reported.
Rahusen et al.8 suggested that redefining micro-
metastasis as lymph node disease  1 mm may pro-
vide better discrimination of patients at low risk for
metastasis in NSNs. Support for this idea is found in a
study that focused exclusively on patients with SN
metastasis  2 mm, subdividing patients by metasta-
sis size in 0.3-mm increments.18 The authors found
that the proportion of patients with positive NSNs was
13–17% for subgroups in which the metastasis was  1
mm compared with 33–38% for subgroups with in
which the metastasis measured1–2 mm. Similarly,
Rahusen et al. found a difference in NSN metastasis
using a 1-mm cutoff for metastasis size( 27% with SN
metastasis  1 mm compared with 50% with SN me-
tastasis  1 mm).8 These values appear high and may
be explained by the use of routine IHC on NSNs, but
they also support consideration of a 1-mm cutoff.
Although current American Joint Committee on Can-
cer criteria define micrometastatic disease as disease
measuring  2 mm, Rahusen et al.8 proposed that a
1-mm delineation may be more clinically relevant
with a goal of discriminating which individuals have a
dramatically lower risk of NSN metastases and could
potentially forego completion ALND.
Despite the findings on univariate analysis, con-
founding of variables is expected, and multivariate
analysis is necessary to develop a model that could
accurately predict the likelihood of positive NSNs in
an individual patient. Unfortunately, without the orig-
inal multivariate data regarding each individual per-
son/patient in each study, we do not believe it is
possible to perform multivariate analysis on the
pooled data for this review. However, a multivariate
model to predict the status of NSNs recently was pro-
posed in an abstract from the Memorial Sloan-Ketter-
TABLE 3
Total Sample Size and Range of Study-Specific Univariate ORs
Covariate Level A (%) Level B (%) Sample size
Range of study-specific ORs,
Comparing Level A with Level B
Minimum Maximum
Age group (yrs)  50 (49) 50 (51) 467 0.63 1.05
Progesterone receptor Negative (38) Positive (62) 290 1.16 1.94
Palpable tumor Yes (72) No (28) 170 0.73 2.00
Tumor grade III (39) I or II (61) 789 0.69 2.38
SNs removed 1 or 2 (62) 3 (38) 520 1.31 2.93
HER-2/neu Positive (25) Negative (75) 165 1.40 2.13
Estrogen receptor Negative (27) Positive (73) 354 1.23 3.57
Histology Lobular (9) Ductal (91) 481 1.45 5.03
Lymphovascular invasion Present (33) Absent (67) 719 0.60 3.62
No. of positive SNs 2 (29) 1 (71) 807 1.98 5.40
Tumor size (cm) 2 (42)  2 (58) 1,334 1.29 11.40
Extranodal extension Present (30) Absent (70) 480 0.97 15.47
Size of metastasis (mm) 2(57)  2 (43) 969 3.64 13.17
ORs: odds ratios; SN: sentinel lymph nodes.
TABLE 4








Weiser et al.7 ● ● 
Wong et al.9 ● ●
Turner et al.10 ● ● ● ● 
Hwang et al.11 ● ●  ● 
Reynolds et al.12 ● ● 
Cserni13 ● ● ●
EE: extranodal extension; LVI: lymphovascular invasion; SN: sentinel lymph node; Solid circle: feature
found to be statistically significant on multivariate analysis; Open circle: feature evaluated, but not
found to be statistically significant by multivariate analysis.
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ing Cancer Center based on a dataset of 702 patients
with positive SNs who underwent completion ALND.26
A nomogram was presented that included nine fac-
tors, with points assigned for each factor. The re-
searchers reported a predictive accuracy of 74% with
this model. EE was not found to be one of the features
included in their model, although it was statistically
significant by univariate analysis in three studies 6,10,13
and by multivariate analysis in one study reviewed
herein.10 We believe the publication of this predictive
model will afford the opportunity to validate it in a
dataset from another institution.
If a low probability of NSN metastasis can be
predicted, a judgment regarding the omission of com-
pletion ALND will remain subject to the opinions of
both physicians and patients. Individuals advocating
elimination of ALND whenever possible will argue that
it may not be necessary to resect residual disease. The
multiple articles reviewed in the current study dem-
onstrate that only 20 –30% of patients with micrometa-
static disease will have metastatic disease in the NSNs.
Some of these patients would receive cytotoxic che-
motherapy or radiation therapy (regardless of the NSN
status), which might successfully eradicate any resid-
ual axillary lymph node disease. Guenther et al.27 re-
ported a low incidence of regional failure in 46 pa-
tients with SN metastases who did not undergo ALND
(mean follow-up of 32 months). Furthermore, Greco et
al.28 documented that axillary lymph node recur-
rences in untreated axillas are less frequent than
would be expected based on the incidence of positive
lymph nodes with ALND, implying that only a small
proportion of patients with histologically detectable
axillary lymph node disease will develop a clinical
recurrence.
In contrast, individuals who support more aggres-
sive surgical management will point out that ALND
improves local disease control and also may provide a
survival benefit. A review of survival data from the
National Cancer Database concerning women with
Stage I and Stage II breast carcinoma demonstrated
that the 10-year survival was significantly worse when
ALND was omitted, and this effect was not completely
the result of understaging.29 However, to our knowl-
edge, data regarding comorbidities that may have in-
fluenced the decision to minimize the aggressiveness
of surgical care were not available. Further support for
ALND is found in a meta-analysis of randomized con-
trolled trials that demonstrated a 5% survival benefit
to ALND, although these patients did not receive ad-
juvant therapy, limiting the applicability of these data
to current practice.30 Another factor that supports
completion ALND is the finding of macroscopic resid-
ual disease in some patients whose SNs have only
micrometastatic disease; among those studies report-
ing this finding, the incidence rate was reported to be
as high as 16%.8,10,17,18 Although it may appear logical
to eliminate completion ALND for patients unlikely to
have positive NSNs, Morrow argues that patients with
small primary tumors and only one to three positive
lymph nodes may be those individuals most likely to
obtain a survival benefit from aggressive locoregional
therapy.31
With the therapeutic value of ALND still in ques-
tion, information regarding the likelihood of metasta-
sis in NSNs can be very helpful when counseling
breast carcinoma patients with positive SNs. The arti-
cles reviewed in the current study underscore the fact
that this is a common issue in clinical practice. Until
results are available from the ACOSOG Z0011 trial
regarding the therapeutic value of ALND, a predictive
model will be valuable to clinicians. The analysis pre-
sented herein suggests that the five characteristics
most strongly associated with NSN metastasis should
be included in prospective databases and in the for-
mulation of a predictive model. The development and
validation of this model will require multivariate anal-
ysis of a large dataset from different institutions. Ef-
forts currently are underway to achieve this goal.
Given the similarity of the data from different institu-
tions in the current review, it is reasonable to be
optimistic concerning the widespread applicability
of a validated predictive model. The use of any
predictive model will nonetheless require clinical
judgment weighing the risks and benefits of com-
pletion ALND.
REFERENCES
1. Petrek JA, Senie RT, Peters M, Rosen PP. Lymphedema in a
cohort of breast carcinoma survivors 20 years after diagno-
sis. Cancer. 2001;92:1368 –1377.
2. Kakuda JT, Stuntz M, Trivedi V, Klein SR, Vargas HI. Objec-
tive assessment of axillary morbidity in breast cancer treat-
ment. Am Surg. 1999;65:995–998.
3. Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A,
Giuliano AE. Do all patients with sentinel node metastasis
from breast carcinoma need complete axillary node dissec-
tion? Ann Surg. 1999;229:536 –541.
4. Liang WC, Sickle-Santanello BJ, Nims TA. Is a completion
axillary dissection indicated for micrometastases in the sen-
tinel lymph node? Am J Surg. 2001;182:365–368.
5. Mantel N, Haenszel W. Statistical aspects of the analysis of
data from retrospective studies of disease. J Natl Cancer Inst.
1959;22:719 –748.
6. Abdessalam SF, Zervos EE, Prasad M, et al. Predictors of
positive axillary lymph nodes after sentinel lymph node
biopsy in breast cancer. Am J Surg. 2001;182:316 –320.
7. Weiser MR, Montgomery LL, Tan LK, et al. Lymphovascular
invasion enhances the prediction of non-sentinel node me-
tastases in breast cancer patients with positive sentinel
nodes. Ann Surg Oncol. 2001;8:145–149.
2314 CANCER December 1, 2003 / Volume 98 / Number 11
8. Rahusen FD, Torrenga H, van Diest PJ, et al. Predictive
factors for metastatic involvement of nonsentinel nodes
in patients with breast cancer. Arch Surg. 2001;136:1059 –
1063.
9. Wong SL, Edwards MJ, Chao C, et al. Predicting the status of
the nonsentinel axillary nodes: a multicenter study. Arch
Surg. 2001;136:563–568.
10. Turner RR, Chu KU, Qi K, et al. Pathologic features associ-
ated with nonsentinel lymph node metastases in patients
with metastatic breast carcinoma in a sentinel lymph node.
Cancer. 2000;89:574 –581.
11. Hwang RF, Krishnamurthy S, Hunt K, et al. Clinicopatho-
logic factors predicting involvement of nonsentinel axillary
nodes in women with breast cancer. Ann Surg Oncol. 2003;
10:248 –254.
12. Reynolds C, Donohue JH, Grant CS, et al. Sentinel lymph
node biopsy with metastasis: can axillary dissection be
avoided in some patients with breast cancer? J Clin Oncol.
1999;17:1720 –1726.
13. Cserni G. Sentinel lymph-node biopsy-based prediction of
further breast cancer metastases in the axilla. Eur J Surg
Oncol. 2001;27:532–538.
14. Kamath VJ, Giuliano R, Dauway EL, et al. Characteristics of
the sentinel lymph node in breast cancer predict further
involvement of higher-echelon nodes in the axilla. Arch
Surg. 2001;136:688 – 692.
15. Mignotte H, Treilleux I, Faure C, Nessah K, Bremond A.
Axillary lymph-node dissection for positive sentinel nodes
in breast cancer patients. Eur J Surg Oncol. 2002;28:623–
626.
16. Canavese G, Gipponi M, Catturich A, et al. Technical issues
and pathologic implications of sentinel lymph node biopsy
in early-stage breast cancer patients. J Surg Oncol. 2001;77:
81– 87.
17. Den Bakker MA, van Weeszenberg A, de Kanter AY, et al.
Non-sentinel lymph node involvement in patients with
breast cancer and sentinel node micrometastasis; too early
to abandon axillary clearance. J Clin Pathol. 2002;55:932–
935.
18. Viale G, Maiorano E, Mazzarol G, et al. Histologic detection
and clinical implications of micrometastases in axillary sen-
tinel lymph nodes for patients with breast carcinoma. Can-
cer. 2001;92:1378 –1384.
19. Sachdev U, Murphy K, Derzie A, Jaffer S, Bleiweiss IJ, Brower
S. Predictors of nonsentinel lymph node metastasis in breast
cancer patients. Am J Surg. 2002;183:213–217.
20. Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopatho-
logic validation of the sentinel lymph node hypothesis for
breast carcinoma. Ann Surg. 1997;226:271–278.
21. Sabel MS, Zhang P, Barnwell JM, Winston JS, Hurd T, Edge
SB. Accuracy of sentinel node biopsy in predicting nodal
status in patients with breast carcinoma. J Surg Oncol 2001;
77:243–246.
22. Chu KU, Turner RR, Hansen NM, Brennan MB, Giuliano AE.
Sentinel node metastasis in patients with breast carcinoma
accurately predicts immunohistochemically detectable
nonsentinel node metastasis. Ann Surg Oncol. 1999;6:756 –
761.
23. Sener SF, Winchester DJ, Martz CH, et al. Lymphedema after
sentinel lymphadenectomy for breast carcinoma. Cancer.
2001;92:748 –752.
24. Grube BJ, Giuliano AE. Observation of the breast cancer
patient with a tumor-positive sentinel node: implications
of the ACOSOG Z0011 trial. Semin Surg Oncol 2001;20:
230 –237.
25. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the
consensus conference on the role of sentinel lymph node
biopsy in carcinoma of the breast, April 19 –22, 2001, Phila-
delphia, Pennsylvania. Cancer. 2002;94:2542–2551.
26. Bevilacqua JL, Manasseh DE, Kattan MW, et al. A multivar-
iate nomogram to predict likelihood of non-sentinel node
metastases in breast cancer patients with positive sentinel
nodes [abstract]. Presented at the Society of Surgical Oncol-
ogy, Los Angeles, California, March 6 –9, 2003.
27. Guenther JM, Hansen NM, DiFronzo LA, et al. Axillary
dissection is not required for all patients with breast
cancer and positive sentinel nodes. Arch Surg. 2003;138:
52–56.
28. Greco M, Agresti R, Cascinelli N, et al. Breast cancer patients
treated without axillary surgery: clinical implications and
biologic analysis. Ann Surg. 2000;232:1–7.
29. Bland KI, Scott-Conner CE, Menck H, Winchester DP. Axil-
lary dissection in breast-conserving surgery for Stage I and II
breast cancer: a National Cancer Data Base study of patterns
of omission and implications for survival. J Am Coll Surg.
1999;188:586 –596.
30. Orr RK. The impact of prophylactic axillary node dissection
on breast cancer survival–a Bayesian meta-analysis. Ann
Surg Oncol. 1999;6:109 –116.
31. Morrow M. A survival benefit from axillary dissection: was
Halsted correct? Ann Surg Oncol. 1999;6:17–18.
NSN Metastasis in Breast Carcinoma/Degnim et al. 2315
